UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

6 Dec 2005

New Data on the Use of Keppra® (levetiracetam) as Adjunctive Treatment in Idiopathic Generalised Epilepsy Patients with Primary Generalised Tonic-Clonic Seizures

Read More
22 Nov 2005

Two Senior Pharma Executives as New Members of UCB's Executive Committee

Read More
17 Nov 2005

Actelion and UCB enter into assignment and license agreement for Zavesca® (miglustat)

Read More
9 Nov 2005

UCB Receives FDA Orphan Drug Designation for Brivaracetam for the Treatment of Symptomatic Myoclonus

Read More
27 Oct 2005

UCB Reports Positive Clinical Trial Results for Keppra® as Adjunctive Therapy in the Treatment of Primary Generalised Tonic-Clonic Seizures

Read More
20 Oct 2005

UCB confirms good performance of Zyrtec in US and Xyzal

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe

© 2007 - 2024 UCB S.A., Belgium. All rights reserved. Last updated on: March, 24, 2024